EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ:SRDX), a medical technology firm with a market capitalization of $424 million, is set to defend its planned merger with affiliates of GTCR LLC in court, ...

Gifting allows recipients to access the article for free. The U.S. Federal Trade Commission has moved to block private-equity firm GTCR’s acquisition of Surmodics Inc., saying the deal would ...

The U.S. Federal Trade Commission (FTC) has moved to block the $627 million acquisition of cardiovascular devicemaker Surmodics by private equity firm GTCR over a potential plan to combine the ...

The U.S. Federal Trade Commission (FTC) has filed a lawsuit to prevent medical device coatings maker Surmodics from merging with private equity firm GTCR, citing concerns over rising healthcare costs.

Surmodics, Inc. (NASDAQ:SRDX), a medical technology firm with a market capitalization of $424 million, is set to defend its planned merger with affiliates of GTCR LLC in court, following the U.S ...

GTCR announced its acquisition of Surmodics for $627 million GTCR invested in Biocoat, a specialty manufacturer of hydrophilic biomaterial coatings, services and dip-coating equipment for medical ...

Additional Information About the Pending Acquisition of Surmodics by funds affiliated with GTCR On May 29, 2024, Surmodics announced it had entered into a definitive merger agreement to be ...